Commercial stage biopharmaceutical company with a transdermal drug delivery platform
Corium (NASDAQ: CORI) was a leader in transdermal delivery systems and related technologies through its platform based on two technologies – MicroCor (large molecules, or biologics, including vaccines, peptides, and proteins) and Corplex (small molecules that were difficult to deliver in transdermal dosage form) – for transporting drugs through the skin for absorption into the body. The company had a GMP production operation in Grand Rapids, Michigan and had completed development through various stages of FDA filings for several therapeutic products for its partners, with 180+ patents issued, published, and pending related to microstructures, polymers, adhesives, transdermal and other drug delivery technologies. Corium’s held partnerships with P&G, Par Pharmaceutical, Teva Pharmaceuticals USA, Agile Therapeutics, amongst others. Gurnet Point Capital acquired Corium in November 2018.
- Menlo Park, CA
- NASDAQ: CORI
- Formerly Known As: Stratagent Life Sciences
- Acquired by: Gurnet Point Capital
- Exit date: November 27, 2018
“With its operational experience, strategic understanding of our business environment and financial strength, Essex Woodlands has been an invaluable partner for Corium. We have worked closely with the EW team through several phases of our development--as we created new products with our transdermal technologies, as we grew our business, and recently as we became a public company.”
Chief Executive Officer
Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.